SCHEMBL349832

SCHEMBL349832

CC(=O)c1nccc2ccccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 5/20 0.56
CYP2A6 P11509 1/20 0.52
RAB9A P51151 3/20 0.51
PDE3B Q13370 1/20 0.47
PDE3A Q14432 1/20 0.47
PLAU P00749 2/20 0.47
F12 P00748 1/20 0.47
NCF1 P14598 1/20 0.47
NOS3 P29474 1/20 0.47
NOS1 P29475 1/20 0.47
NOS2 P35228 1/20 0.47
BACE1 P56817 1/20 0.47
MAPT P10636 3/20 0.45
TSHR P16473 2/20 0.45
MEN1 O00255 1/20 0.45
TP53 P04637 1/20 0.45
KMT2A Q03164 1/20 0.45
ALDH1A1 P00352 3/20 0.44
HPGD P15428 1/20 0.44
CYP3A4 P08684 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4404077 0.84 CNR2 (0.64) CNR2CYP2A6RAB9APLAUF12
SCHEMBL5357601 0.82 CNR2 (0.54) CNR2CYP2A6RAB9APLAUF12
SCHEMBL287165 0.82 RAB9A (0.56) CNR2CYP2A6RAB9APLAUF12
SCHEMBL25482213 0.82 CYP2A6 (0.53) CNR2CYP2A6RAB9APLAUF12
SCHEMBL8250524 0.81 CYP2A6 (0.52) CNR2CYP2A6RAB9APLAUF12
SCHEMBL970997 0.81 CNR2 (0.53) CNR2CYP2A6RAB9APLAUF12
SCHEMBL111310 0.81 CNR2 (0.53) CNR2CYP2A6RAB9APLAUF12
SCHEMBL29358323 0.81 CNR2 (0.53) CNR2CYP2A6RAB9APLAUF12
SCHEMBL22664584 0.81 RAB9A (0.55) CNR2CYP2A6RAB9APLAUF12
SCHEMBL28492272 0.81 CNR2 (0.53) CNR2CYP2A6RAB9APLAUF12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4581071-A1 METHOD FOR PRODUCING A MATERIAL FOR A MEMBRANE, MATERIAL, MEMBRANE AND USE OF A MEMBRANE Forschungszentrum Jülich GmbH (DE) 2025-07-09 EP claimed
WO-2024046712-A1 METHOD FOR PRODUCING A MATERIAL FOR A MEMBRANE, MATERIAL, MEMBRANE AND USE OF A MEMBRANE Forschungszentrum Jülich GmbH (DE) 2024-03-07 WO claimed
EP-4581071-A1 METHOD FOR PRODUCING A MATERIAL FOR A MEMBRANE, MATERIAL, MEMBRANE AND USE OF A MEMBRANE Forschungszentrum Jülich GmbH (DE) 2025-07-09 EP disclosed
CN-115380030-B N-heteroarylalkyl-2- (heterocyclyl and heterocyclylmethyl) acetamide derivatives as SSTR4 agonists 武田药品工业株式会社 2025-05-16 CN disclosed
US-20250100981-A1 Cis-substituted 5-(hydroxymethyl)morpholine-2-carboxamides as agonists of SSTR4 BOEHRINGER INGELHEIM INT (DE) 2025-03-27 US disclosed
WO-2025027049-A1 (2S,5R)-5-(HYDROXYMETHYL)MORPHOLINE-2-CARBOXAMIDES AS AGONISTS OF SSTR4 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-02-06 WO disclosed
CN-119019327-A Acetylation method of quinoline or isoquinoline compounds 常州工程职业技术学院 2024-11-26 CN disclosed
WO-2024046712-A1 METHOD FOR PRODUCING A MATERIAL FOR A MEMBRANE, MATERIAL, MEMBRANE AND USE OF A MEMBRANE Forschungszentrum Jülich GmbH (DE) 2024-03-07 WO disclosed
CN-114796013-B Oil control composition and application thereof in cosmetics 华熙生物科技股份有限公司 2023-10-20 CN disclosed
EP-4242196-A1 METHOD FOR PREPARING DEUTERATED ANTHRACENE COMPOUND, REACTION COMPOSITION, DEUTERATED ANTHRACENE COMPOUND AND COMPOSITION Lg Chem, Ltd. (KR) 2023-09-13 EP disclosed
US-11697755-B2 Degradable tags for depth correlation mud logging ARAMCO SERVICES COMPANY (US) 2023-07-11 US disclosed
US-6248782-B1 ADMINISTERING ENZYME INHIBITOR ELFORD HOWARD L (US) 2001-06-19 US disclosed
US-6043248-A VIRICIDES FOR TREATING AN INDIVIDUAL INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS PHARMACIA & UPJOHN COMPANY (US) 2000-03-28 US disclosed
EP-0664795-B1 PROPENOIC ACID DERIVATIVES USEFUL AS FUNGICIDES ZENECA LTD (GB) 1998-07-01 EP disclosed
CN-1183773-A Alpha-substituted pyrimidine-thioalkyl and alkylether compounds UPJOHN CO (US) 1998-06-03 CN disclosed
US-5723473-A Propenoic acid derivatives useful as fungicides ZENECA LIMITED (GB) 1998-03-03 US disclosed
EP-0824524-A1 ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE PHARMACIA & UPJOHN COMPANY (US) 1998-02-25 EP disclosed
WO-1996035678-A1 ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE PHARMACIA & UPJOHN COMPANY (US) 1996-11-14 WO disclosed
EP-0664795-A1 PROPENOIC ACID DERIVATIVES USEFUL AS FUNGICIDES ZENECA LIMITED (GB) 1995-08-02 EP disclosed
WO-1994008968-A1 PROPENOIC ACID DERIVATIVES USEFUL AS FUNGICIDES ZENECA LIMITED (GB) 1994-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250100981-A1 Cis-substituted 5-(hydroxymethyl)morpholine-2-carboxamides as agonists of SSTR4 SSTR4, SSTR5, SSTR2 CNR2 51/4885CYP2A6 1848/4885RAB9A 1409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.